SRR12696776
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ALLOGRAFT_REJECTION+0.400
- ANGIOGENESIS+0.400
- COMPLEMENT+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MYOGENESIS+0.400
- TGF_BETA_SIGNALING+0.400
- APICAL_JUNCTION+0.300
- HEME_METABOLISM+0.300
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- SPERMATOGENESIS-0.400
- MYC_TARGETS_V2-0.300
- GLYCOLYSIS-0.200
- MYC_TARGETS_V1-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- HEDGEHOG_SIGNALING-0.100
- KRAS_SIGNALING_DN-0.100
- MTORC1_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696751 | — | — | 0.873 |
| 2 | BS_69V8P8A0 | Neurofibroma | — | 0.872 |
| 3 | SRR5088860 | — | — | 0.870 |
| 4 | BS_GDHH6T5A | Neurofibroma | — | 0.866 |
| 5 | BS_B7QS4DHK | Schwannoma | — | 0.866 |
| 6 | BS_Y3G1X98S | Meningioma | — | 0.861 |
| 7 | MDT-AP-2021 | Med | Medulloblastoma | 0.860 |
| 8 | BS_NDC69214 | Neurofibroma | — | 0.859 |
| 9 | SRR6013602 | — | cohortMD2 | 0.858 |
| 10 | SRR1797296 | — | cohortMD2 | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |